UNICREDIT BANK/CALL/AMGEN/250/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 03:41:24 2024-07-12 pm EDT | ||
| 8 EUR | +8.55% |
|
| Current month | +24.22% | ||
| 1 month | +48.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 8 | +8.55% |
| 24-07-11 | 7.37 | +4.99% |
| 24-07-10 | 7.02 | +7.67% |
| 24-07-09 | 6.52 | +3.66% |
| 24-07-08 | 6.29 | +1.45% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3JAJ |
| ISIN | DE000HC3JAJ4 |
| Date issued | 2023-01-26 |
| Strike | 250 $ |
| Maturity | 2024-12-18 (158 Days) |
| Parity | 10 : 1 |
| Emission price | 3.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.04 € |
|---|---|
| Lowest since issue | 1.33 € |
| Spread | 0.03 € |
| Spread % | 0.38% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
330.8
USD
Average target price
317.4
USD
Spread / Average Target
-4.06%
- Stock Market
- Warrants
- Warrant
